Therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
;
(12): 708-710, 2005.
Article
Dans Chinois
| WPRIM
| ID: wpr-813442
ABSTRACT
OBJECTIVE@#To evaluate the therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia (BPH).@*METHODS@#Two hundreds and twenty-two patients with BPH were randomly assigned into 2 groupsharnal (0.2 mg/d) group (n = 112) and proscar (5 mg/d) group (n = 108). American Urologic Association Symptom Index (AUA-SI) scores, the maximal urinary flow rate (Qmax) and prostatic volume were analyzed in the 2 groups.@*RESULTS@#After 12 weeks of treatment, 54.5% of the harnal group improved in AUA-SI score; 54.6% of the proscar group improved in AUA-SI score; and there was no significant difference between the 2 groups (P > 0.05). After 24 weeks of treatment, the proscar group (79.6%) had a greater improvement in AUA-SI score than the harnal group (64.3%) (P < 0.05); Qmax in the 2 groups was significantly increased than that before the treatment, and it is proportional to the therapeutic time. The prostatic volume in 2 groups had no significant change.@*CONCLUSION@#Harnal and proscar can significantly improve BPH symptoms and the urinary flow rate. The therapeutic effect of harnal and proscar has their own characteristics.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Hyperplasie de la prostate
/
Troubles mictionnels
/
Urodynamique
/
Finastéride
/
Antagonistes alpha-adrénergiques
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Inhibiteurs de la 5-alpha réductase
Limites du sujet:
Adulte très âgé
/
Humains
/
Mâle
langue:
Chinois
Texte intégral:
Journal of Central South University(Medical Sciences)
Année:
2005
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS